Research News and Research

RSS

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

CQ HealthBeat: "Education or propaganda? Or 'beyond propaganda?' The Centers for Medicare and Medicaid Services announced Monday that it will soon send Medicare beneficiaries a special mailing on 'the immediate benefits they may see' from the health care overhaul law. Getting accurate information about key provisions of the law will help Medicare enrollees 'to be on the alert for any scams asking for personal information,' explained acting CMS Administrator Marilyn Tavenner in an agency news release Monday.

25 May 2010

State regulators mull definition of medical loss ratio

News outlets report on efforts to define what will be considered "medical expenses" when it comes to the mandated medical loss ratios in the new health law.

25 May 2010

Experts question 'doc fix' as Reid threatens weekend work on bill with COBRA, Medicare provisions

Politico: Experts are questioning the virtues of the three-year Medicare "doc fix" that would stave off cuts to Medicare doctors' pay but set up a larger fight down the road. ... In health policy circles, the 'doc fix' has become emblematic of Washington's worst habits: a potentially solvable policy problem run amok for about a decade now, bogged down in pure politics and accounting gimmicks. The 'doc fix,' a last-minute infusion of funds to head off a looming doctor pay cut under Medicare, hits the floor this week via the tax extenders bill ..."

25 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

DOJ warns hospitals, insurers: Mergers will be scrutinized

The Obama administration warned the health care industry Monday that it "won't hesitate to block mergers that threaten to stifle competition," The Associated Press reports.

25 May 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.

25 May 2010

First Edition: May 25, 2010

Today's headlines reflect health policy action at the federal level as the Obama administration issues a warning to the insurance industry about mergers and urges the courts to dismiss Virginia's lawsuit against the health reform law.

25 May 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.

25 May 2010

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

The Biotechnology Industry Organization (BIO) praised the Obama Administration for its new guidance, released today, that will lead to many small biotechnology companies receiving needed funding to support critical on-going research and development programs. The guidance document initiates the Therapeutic Discovery Project Program (TDPP), which was created by the Patient Protection and Affordable Care Act signed into law by President Obama on March 23.

25 May 2010

CCO announces 2010 Research Chairs program

Six Ontario Researchers have received funding of $500,000 OR $1 million to further cancer research over the next five years, Cancer Care Ontario's Research Program announced today.

25 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

Significant progress on international development strategy for stem cell-derived human corneal tissue

International Stem Cell Corporation, www.intlstemcell.com, today announced significant progress on its international development strategy for stem cell-derived human corneal tissue. Such tissue can potentially be used to replace cadaver-derived corneas in treatment of severe corneal vision impairment and to eliminate the need to use live animals in safety testing of drugs, chemicals and consumer products.

25 May 2010

GATOR approach helps assess health information websites

Patients researching health conditions on the internet should use reputable and frequently updated websites and not see online research as a replacement for consulting healthcare professionals, according to a paper in the May issue of the Journal of Clinical Nursing.

25 May 2010

New campaign to raise awareness about soul wrenching realities of Alzheimer's disease

The Alzheimer Society is launching a new campaign in an effort to raise awareness about the soul wrenching realities of Alzheimer's disease, and the Society's efforts to fund research towards a cure.

25 May 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).

25 May 2010

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Drug discovery and development is a highly risky process, with only one in 10,000 initial candidate compounds reaching the market. When taking into account the aborted candidates, the cost of developing one successful drug may even reach $1 billion, and the development process may take as long as 15-20 years.

25 May 2010

Researchers study how hematopoietic cells react when Epo levels increase

Our body reacts to blood loss by stimulating the production of red blood cells (erythrocytes). The cells of the hematopoietic (blood-forming) system in the bone marrow do so upon receipt of a signal by a hormone called erythropoietin, or Epo for short. This hormone is produced mainly by the kidney that increases the Epo level by up to a thousand-fold as a response to falling oxygen saturation of the blood.

25 May 2010

Nutritious gluten-free breads for coeliac disease patients

Researchers at Teagasc Food Research Ashtown are producing tasty, nutritious gluten-free breads for coeliac disease sufferers. The research focused on using the so-called 'pseudocereals' amaranth, quinoa and buckwheat to replace wheat in bread formulations. These cereals are gluten-free, and are also rich in nutrients; therefore, their incorporation in the gluten-free diet could not only add variety but also improve nutritional quality.

25 May 2010

Research News and Research

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

State regulators mull definition of medical loss ratio

Experts question 'doc fix' as Reid threatens weekend work on bill with COBRA, Medicare provisions

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

DOJ warns hospitals, insurers: Mergers will be scrutinized

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

First Edition: May 25, 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

CCO announces 2010 Research Chairs program

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Significant progress on international development strategy for stem cell-derived human corneal tissue

GATOR approach helps assess health information websites

New campaign to raise awareness about soul wrenching realities of Alzheimer's disease

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Researchers study how hematopoietic cells react when Epo levels increase

Nutritious gluten-free breads for coeliac disease patients

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence